Study of an Investigational Pneumococcal Vaccine at Three Dose Levels in Healthy Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-06-30

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is designed to evaluate the safety, tolerability, and immunogenicity of an investigational pneumococcal vaccine in healthy adult volunteers.

Primary Objective:

* To evaluate the safety and tolerability of an investigational pneumococcal vaccine.

Observational Objective:

* To evaluate the immunogenicity of an investigational Pneumococcal vaccine.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Two Investigational Pneumococcal Vaccines in Healthy Adults

NCT01444339

Pneumococcal Infections Streptococcus Pneumoniae Infections Pneumococcal Pneumonia

COMPLETED PHASE1

Study of an Investigational Pneumococcal Vaccine in Healthy Adult Volunteers

NCT01444001

Pneumococcal Infections Pneumococcal Pneumonia

COMPLETED PHASE1

Study of Investigational Pneumococcal Vaccine in Healthy Adults, Toddlers and Infants

NCT01446926

Pneumonia Pneumococcal Infections Streptococcus Pneumoniae Infections

COMPLETED PHASE1

Immunological Persistence After Priming With GSK1024850A Vaccine and Safety& Immunogenicity After Booster Dose

NCT01119625

Infections, Streptococcal

COMPLETED PHASE3

Study Evaluating the Effiacy of a 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) in Adults

NCT00744263

Pneumonia, Pneumococcal Pneumococcal Infections 13-valent Pneumococcal Vaccine

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

An initial cohort of 10 participants will receive a single dose of investigational pneumococcal vaccine. After safety assessment of this cohort during a 24-hour in-unit observation period, additional cohorts will receive two injections of the study vaccine 30 days apart, at three dose levels, in ascending doses by cohort, pending safety review at each dose level. All participants will be monitored for safety for 30 days after each vaccination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pneumococcal Infections Streptococcus Pneumoniae Infections Pneumococcal Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaccine Formulation 1 (Low dose)

Participants will receive 2 injections of Pneumococcal Vaccine Formulation 1 (Low dose).

Group Type EXPERIMENTAL

Pneumococcal vaccine Formulation 1

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular (Low dose)

Vaccine Formulation 2 (Middle dose)

Participants will receive 2 injections of Pneumococcal Vaccine Formulation 2, (Middle dose).

Group Type EXPERIMENTAL

Pneumococcal vaccine Formulation 2

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular (Middle dose)

Vaccine Formulation 3 (High dose)

Participants will receive 2 injections of Pneumococcal Vaccine Formulation 3, (High dose).

Group Type EXPERIMENTAL

Pneumococcal vaccine Formulation 3

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular (High dose)

Placebo Pooled

Participants who receive 2 injections of tris buffered saline

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

0.5 mL, Intramuscular

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pneumococcal vaccine Formulation 1

0.5 mL, Intramuscular (Low dose)

Intervention Type BIOLOGICAL

Pneumococcal vaccine Formulation 2

0.5 mL, Intramuscular (Middle dose)

Intervention Type BIOLOGICAL

Pneumococcal vaccine Formulation 3

0.5 mL, Intramuscular (High dose)

Intervention Type BIOLOGICAL

Placebo

0.5 mL, Intramuscular

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Tris Buffered Saline

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18 to 50 years on the day of inclusion
* Informed consent form has been signed and dated
* Able to attend all scheduled visits and comply with all trial procedures
* Subject is healthy, as determined by medical history and physical examination
* For a woman of child-bearing potential, use of an effective method of contraception or abstinence from at least 4 weeks prior to first vaccination until 4 weeks after the last vaccination.

Exclusion Criteria

* History of anaphylactic reaction or asthma
* Unknown pregnancy or positive serum/urine pregnancy test
* Currently breastfeeding a child
* Chronic illness, that in the opinion of the investigator, is at a stage that could interfere with trial conduct or completion
* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination
* Planned participation in another clinical trial during the present trial period
* Known or suspected congenital or acquired immunodeficiency, receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
* Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances
* Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures
* Receipt of blood or blood-derived products in the past 3 months, that might interfere with the assessment of immune response
* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination, except for pandemic influenza vaccination which may be received at least two weeks before the study vaccines
* Planned receipt of any vaccine in the 4 weeks following the trial vaccination, except for pandemic influenza vaccination in the event of a local or national immunization program
* Known seropositivity for Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C
* Laboratory confirmed/self-reported thrombocytopenia contraindicating intramuscular (IM) vaccination
* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
* Identified as a study site employee who is involved in the protocol and may have direct access to trial-related data
* Previous vaccination against pneumococcal disease (in the previous 5 years)
* History of pneumococcal infection (confirmed either clinically, serologically, or microbiologically) within 5 years
* At high risk for pneumococcal infection during the trial
* Living in a household with children \<5 years of age.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes